CHINA PHARMA HOLDINGS, INC. Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Amount
CHINA PHARMA HOLDINGS, INC. (CPHI) reported Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Amount of $23.30 million for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-14.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary · last filed 2017-11-14
- CHINA PHARMA HOLDINGS, INC. effective income tax rate reconciliation, equity in earnings (losses) of unconsolidated subsidiary, amount for the quarter ending 2017-09-30 was $0.00.
| Period end | Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Amount 3 month | Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Amount 6 month | Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Amount 9 month |
|---|---|---|---|
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | $23.30M 10-Q · filed 2017-11-14 | |
| 2017-06-30 | $23.30M 10-Q · filed 2017-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |